CN1958093A - Application of photosensitizer for high temperature focused ultrasonic sensitization agent - Google Patents
Application of photosensitizer for high temperature focused ultrasonic sensitization agent Download PDFInfo
- Publication number
- CN1958093A CN1958093A CN 200510115551 CN200510115551A CN1958093A CN 1958093 A CN1958093 A CN 1958093A CN 200510115551 CN200510115551 CN 200510115551 CN 200510115551 A CN200510115551 A CN 200510115551A CN 1958093 A CN1958093 A CN 1958093A
- Authority
- CN
- China
- Prior art keywords
- photosensitizer
- high intensity
- focused ultrasound
- intensity focused
- sensitizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 84
- 239000003795 chemical substances by application Substances 0.000 title claims description 4
- 206010070834 Sensitisation Diseases 0.000 title description 2
- 230000008313 sensitization Effects 0.000 title description 2
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 22
- 230000003902 lesion Effects 0.000 claims abstract description 5
- 238000002604 ultrasonography Methods 0.000 claims description 75
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 239000000126 substance Substances 0.000 claims description 16
- 241001597008 Nomeidae Species 0.000 claims description 12
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 239000012752 auxiliary agent Substances 0.000 claims description 10
- 230000014759 maintenance of location Effects 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000011162 core material Substances 0.000 claims description 8
- 239000007789 gas Substances 0.000 claims description 8
- 230000008520 organization Effects 0.000 claims description 8
- 230000008021 deposition Effects 0.000 claims description 7
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 claims description 6
- YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- -1 fluorine carbon hydrocarbon Chemical class 0.000 claims description 6
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims description 6
- KGHNSNSWRMJVND-UHFFFAOYSA-N Hypocrellin Natural products COC1=CC(=O)C2=C3C4C(C(C(=O)C)C(C)(O)Cc5c(OC)c(O)c6C(=O)C=C(OC)C(=C13)c6c45)C(=C2O)OC KGHNSNSWRMJVND-UHFFFAOYSA-N 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- VANSZAOQCMTTPB-SETSBSEESA-N hypocrellin Chemical compound C1[C@@](C)(O)[C@@H](C(C)=O)C2=C(OC)C(O)=C3C(=O)C=C(OC)C4=C3C2=C2C3=C4C(OC)=CC(=O)C3=C(O)C(OC)=C21 VANSZAOQCMTTPB-SETSBSEESA-N 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- BQJKVFXDDMQLBE-UHFFFAOYSA-N shiraiachrome A Natural products COC1=C2C3=C(OC)C=C(O)C4=C3C3=C5C(CC(C)(O)C(C(C)=O)C3=C(OC)C4=O)=C(OC)C(=O)C(C(O)=C1)=C25 BQJKVFXDDMQLBE-UHFFFAOYSA-N 0.000 claims description 5
- 229930192474 thiophene Natural products 0.000 claims description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- 206010067193 Naevus flammeus Diseases 0.000 claims description 4
- 208000006787 Port-Wine Stain Diseases 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 208000002026 familial multiple nevi flammei Diseases 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 claims description 4
- 150000004032 porphyrins Chemical class 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000010282 Emodin Substances 0.000 claims description 3
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 claims description 3
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 claims description 3
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 claims description 3
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical class C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 3
- 229930002875 chlorophyll Natural products 0.000 claims description 3
- 235000019804 chlorophyll Nutrition 0.000 claims description 3
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 3
- 239000004148 curcumin Substances 0.000 claims description 3
- 235000012754 curcumin Nutrition 0.000 claims description 3
- 229940109262 curcumin Drugs 0.000 claims description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 3
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 claims description 3
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 claims description 3
- 241000411851 herbal medicine Species 0.000 claims description 3
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims description 3
- 229940005608 hypericin Drugs 0.000 claims description 3
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims description 3
- 230000002427 irreversible effect Effects 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 claims description 3
- 229920001197 polyacetylene Chemical class 0.000 claims description 3
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical class C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims description 3
- 150000004053 quinones Chemical class 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 230000001235 sensitizing effect Effects 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 150000003577 thiophenes Chemical class 0.000 claims description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- PRPAGESBURMWTI-UHFFFAOYSA-N [C].[F] Chemical compound [C].[F] PRPAGESBURMWTI-UHFFFAOYSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229910003472 fullerene Inorganic materials 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 238000006552 photochemical reaction Methods 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 23
- 230000001225 therapeutic effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- 238000007539 photo-oxidation reaction Methods 0.000 description 4
- 238000002428 photodynamic therapy Methods 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 206010019695 Hepatic neoplasm Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- HUVXQFBFIFIDDU-UHFFFAOYSA-N aluminum phthalocyanine Chemical compound [Al+3].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 HUVXQFBFIFIDDU-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- APTUSGMALOMQQL-UHFFFAOYSA-N chembl2029624 Chemical compound O=C1C(OC)=C2C(C(C)=O)=C(C)CC3=C(OC)C(=O)C4=C(O)C=C(OC)C5=C4C3=C2C2=C1C(O)=CC(OC)=C25 APTUSGMALOMQQL-UHFFFAOYSA-N 0.000 description 2
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- MHIITNFQDPFSES-UHFFFAOYSA-N 25,26,27,28-tetrazahexacyclo[16.6.1.13,6.18,11.113,16.019,24]octacosa-1(25),2,4,6,8(27),9,11,13,15,17,19,21,23-tridecaene Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- SBMXTMAIKRQSQE-UHFFFAOYSA-N Hypocrellin C Natural products O=C1C=C(OC)C2=C(C3=C45)C(OC)=CC(=O)C3=C(O)C(OC)=C4C(C(C)=O)=C(C)CC3=C5C2=C1C(O)=C3OC SBMXTMAIKRQSQE-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- YDLBDQPPRTYAIG-UHFFFAOYSA-N hypocrellin A Natural products COC1C2CC(C)(O)C(C(=O)C)C3=C(OC)C(=O)c4c(O)cc(OC)c5c6c(OC)cc(O)c(C1=O)c6c2c3c45 YDLBDQPPRTYAIG-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- BBNQQADTFFCFGB-UHFFFAOYSA-N purpurin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of photosensistizer as the sensitizer of focused high-intensity ultrasonic therapy is disclosed. Said photosensitizer is activated by the focused high-intensity ultrasonic waves to generate photochemical reaction which can destroy the lesion tissue, so improving curative effect.
Description
Technical field
The invention belongs to the ultrasonic therapeutic technical field, more particularly, the present invention relates to the new purposes of photosensitizer as the high intensity focused ultrasound sensitizer.
Background technology
Photoactive substance is that a class contains photosensitive composition traditionally, can be activated by certain wavelength light any material that photooxidation reaction produces active oxygen takes place.Among the present invention related photosensitizer be contain photosensitive composition can selectivity very/neoplasm sex organization in retention and can be by the photoactivation of certain wavelength under produce the photoactive substance of active oxygen lethality proliferative tissue cell, be mainly used in the optical dynamic therapy of good/neoplasm disease.(Photodynamic Therapy PDT) is development in recent years oncotherapy new technique rapidly to optical dynamic therapy.Its basic skills is that photosensitizer is imported in the human body; make it behind certain hour morely in the tumor inner accumulated; this moment is with the rayed tumor locus of specific wavelength; in tissue under the participation of oxygen; cause photooxidation reaction, produce very active active oxygen species of chemical property or free radicals such as singlet oxygen, attack important biomolecule such as destroying albumen, lipid, nucleic acid; finally make death of neoplastic cells, reach therapeutic purposes.Photosensitizer commonly used among the PDT is a porphyrin substance, and its tetrapyrrole macro ring absorbs the 600-800nm HONGGUANG, causes photooxidation reaction.Photosensitizer also has phthalocyanine and derivant, chlorophyll and derivant thereof, quinones, endogenous photosensitizers 5-amino-laevulic acid, rose-red, polyacetylene class such as benzene alkynes in heptan three, thiophenes such as α thiophene, Chinese herbal medicine class such as hypocrellin derivant, psoralen class, curcumin, hypericin, pseudohypericin, emodin, riboflavin, aloe-emodin except porphyrin and derivant thereof.Described proliferative tissue is to become before the benign tumor tissue, malignant tumor tissue, cancer and non-tumprigenicity hyperplasia sex organization such as pathologic cicatrix, nevus flammeus, postangioplasty restenosis etc.
The high intensity focused ultrasound technology has obtained clinical approval as a kind of new method for the treatment of tumor and other diseases.It passes through concentration ultrasonic, on focus, form high strength, continuous ultrasound energy, thereby produce transient high temperature effect (70～100 ℃), cavitation effect, mechanical effect and sonochemical effect, optionally make the lesion tissue coagulation necrosis, the ability that makes tumor lose propagation, soak into and shift.
There are some researches show that ultrasound wave is in the process that tissue is propagated, its energy is exponential decay (people such as Liu Baoqin, Chinese ultrasound medicine magazine, 2002,18 (8): 565-568) with the increase of propagation distance.In addition, the energy attenuation that ultrasound wave is propagated in soft tissue comes self-organizing absorption, scattering, refraction, diffraction etc., wherein topmost energy loss come from absorb and scattering (Feng as if, the Wang Zhibiao chief editor, practical ultrasonic therapeutic, Beijing: Chinese science technical literature publishing house, 2002.14).Therefore, during tumor that utilization high intensity focused ultrasound technology treatment position is dark, volume is bigger, because that the decay of energy will cause arriving the energy of target area is on the low side, therapeutic efficiency descends, and treatment time prolongs.
Certainly, in order to improve therapeutic efficiency, though can merely strengthen the transmitting power of ultrasonic transducer,, the probability that the normal structure on the ultrasonic propagation passage is burnt has just increased greatly.
In addition, when the liver neoplasm that rib stops is arranged on utilization high intensity focused ultrasound technology treatment sound passage at present clinically, in order to increase the energy deposition of treatment target area, improve treatment speed and therapeutic effect, often to behind the rib on the excision sound passage, treat again, this runs counter to the theory of high intensity focused ultrasound non-invasive therapy, thus be difficult to obtain patient and doctor with can.
The existence of these factors must influence and limit high intensity focused ultrasound popularizing as a clinical applicable technology to a certain extent.Therefore, seek the high intensity focused ultrasound sensitizer and how further explore improve high intensity focused ultrasound to the therapeutic effect of malignant tumor and reduce its complication be high-strength focusing ultrasonic therapy good/neoplasm advancing of disease trend, also be the important research direction that high-strength focusing ultrasonic therapy is learned.
Summary of the invention
The objective of the invention is and photosensitizer will be used as the high intensity focused ultrasound sensitizer, improve high intensity focused ultrasound to very/neoplasm treatment of diseases effect and reduce the generation of its complication, expand the application of photosensitizer.
The technical scheme that realizes the object of the invention is the application of this photosensitizer as the high intensity focused ultrasound sensitizer, allow the photosensitizer selectivity very/neoplasm sex organization in retention, change the acoustic enviroment of target tissue by its selectivity target area retention effect, increase the target area ultrasound energy deposition, reduce high-strength focusing ultrasonic therapy dosage, activate photosensitizer generation phonochemical reaction with high intensity focused ultrasound and produce active oxygen and the irreversible damage pathological tissues, by sonochemistry mechanism strengthen high-strength focusing ultrasonic therapy good/neoplasm treatment of diseases effect.
Photosensitizer of the present invention be a kind of can selectivity very/neoplasm sex organization in the sensitizer of retention, not only can increase the target area ultrasound energy deposition by its selectivity target area retention effect, also can be activated and phonochemical reaction generation active oxygen take place and the irreversible damage pathological tissues by high intensity focused ultrasound, having the high intensity focused ultrasound enhancement effect, is a kind of energy collecting deposition harmony chemical sensitization high intensity focused ultrasound sensitizer.
In the present invention, described photosensitizer as sensitizer be safety non-toxic can selectivity very/neoplasm sex organization in retention and can be produced the photosensitizer that photooxidation reaction generates reactive oxygen species by light or sound activation, these materials are hydrophilic, lipophile, amphipathic photosensitizer.These materials are photosensitizer of intravenous injection, intra-arterial injection, local injection application.Described reactive oxygen species is a singlet oxygen.To not having too much restriction with the type of photosensitizer as high-strength focusing ultrasonic therapy, as long as this photosensitizer can be distributed in this target tissue by selectivity after being administered to target tissue, under the effect of high intensity focused ultrasound phonochemical reaction can take place, the therapeutic effect that strengthens high intensity focused ultrasound gets final product.Thereby, the photosensitizer that is used for the sensitizer of high-strength focusing ultrasonic therapy of the present invention is selected from porphyrin and derivant such as hemoporphyrin, benzoporphyrin derivative list acid ring A etc., phthalocyanine and derivant thereof such as zinc phthalocyanine and aluminum phthalocyanine etc., chlorophyll and derivant thereof such as pheophytin and chlorin and C.I. Natural Red 8 18, endogenous photosensitizers 5-amino-laevulic acid, rose-red, phycobniliprotein class photosensitizer such as phycoerythrin and phycocyanin etc., the quinones photosensitizer, fullerene, five nitrogen tooth derivatives class photosensitizer such as lutecium III five nitrogen teeth, polyacetylene class photosensitizer such as benzene alkynes in heptan three, thiophenes photosensitizer such as α thiophene, Chinese herbal medicine class photosensitizer such as hypocrellin and derivant thereof are (as hypocrellin A, hypocrellin B etc.), psoralen class and curcumin, hypericin, pseudohypericin, emodin, riboflavin, a kind of and wantonly two kinds or multiple mixture in the aloe-emodin etc., and any one or more photosensitizer and Chinese patent application numbers 200510000345.8 wherein, the applying date: arbitrary or multiple the combining of the high intensity focused ultrasound auxiliary agent that provides in the patent application on January 10th, 2005 and the photoactive substance that forms.Describedly combine the continuous phase that the high intensity focused ultrasound auxiliary agent that forms photoactive substance comprises that the discontinuous phase that is made of filmogen parcel core and aqueous medium constitute with photosensitizer, wherein said discontinuous phase is evenly dispersed in the described continuous phase, the particle diameter of described discontinuous phase is 5nm～15 μ m, preferred 8nm～10 μ m.The filmogen of described auxiliary agent has biocompatibility, and the material of described core adopts gas, liquid or nano grade biological compatibility solid.Wherein said filmogen is one or more materials in lipid, protide and the saccharide.Described lipid is selected from the 3-sn-phosphatidylcholine, 1 in the phospholipid; 2-two palmityls-sn-glyceryl-3-phosphatidyl glycerol base-sodium salt, 1; 2-distearyl acyl group-sn-glyceryl-3-phosphatidylcholine, 1; 2-two palmityls-sn-glyceryl-3-phosphatidyl acid-sodium salt, 1, one or more in 2-two palmityls-sn-glyceryl-3-phosphatidylcholine, Phosphatidylserine or the hydrogenated phospholipid acyl serine.The gas that described core material adopts is selected from air, nitrogen, one or more in carbon dioxide, fluorine carbon appropriate hydrocarbon gas or the alkanes gas.The liquid that described core material adopts is selected from C
5-C
6Alkane, C
5-C
12In fluorine carbon hydrocarbon, satisfied fatty acid, unsaturated fatty acid or the iodized oil one or more.
In addition, in order to make high intensity focused ultrasound sensitizer targeting of the present invention specific tumor tissues such as liver tumor, tumor of kidney, bone tumor, breast carcinoma and hysteromyoma etc., also can add the material that described tumor tissues or lesions position is had pathoklisis in as the photosensitizer of sensitizer, the targeting sensitizing agent that forms as the antibody of identification tumor, peptide etc. at this.
Utilize photoactive substance to increase the method for high-strength focusing ultrasonic therapy effect as sensitizer, be before high-strength focusing ultrasonic therapy is carried out in patient's target area 0～168 hour, by in intravenous drip or the target tissue directly mode such as injection give the above-described photoactive substance of patient infusion as sensitizer.
Widely used various photosensitizer and deutero-any photoactive substance thereof all can be used as high-strength focusing ultrasonic therapy sensitizer of the present invention in the photodynamic therapy field at present; In addition, phonochemical reaction takes place and produces reactive oxygen species in this class photoactive substance under ultrasonic activation, can damage the target tissue vascular endothelial cell, starts endogenous or extrinsic coagulation system thromboembolism blood capillary.Thereby the present invention also provides a kind of new method of utilizing photoactive substance combining ultrasonic embolotherapy tumor, nevus flammeus.Promptly utilize the method for photoactive substance as sensitizer combining ultrasonic ripple embolotherapy tumor, nevus flammeus, be before ultrasonic irradiation is carried out in patient's target area 0～168 hour, by in intravenous drip or the target tissue directly injection mode give the above-described photoactive substance of patient infusion.Described ultrasound wave is for focusing on treatment that maybe can not focus on or the ultrasound wave of diagnosing usefulness, and its energy can be a low-intensity or also high-intensity.
The various auxiliary agents of existing high intensity focused ultrasound enhanced sensitivity mainly are to increase target area ultrasound energy deposition effect according to it.Compare with existing high intensity focused ultrasound auxiliary agent, the photosensitizer that is used as the high intensity focused ultrasound sensitizer among the present invention has very/the selectivity retention effect of neoplasm sex organization, not only can increase the target area ultrasound energy deposition by selectivity, strengthen the high-strength focusing ultrasonic therapy effect but also can under ultrasonic activation, produce sonochemistry mechanism, significantly reduce high-strength focusing ultrasonic therapy dosage, reduce the generation of its complication.Its enhancement effect is that existing high intensity focused ultrasound auxiliary agent is incomparable.Utilize photosensitizer will make to treat deep tumor and under the situation of the rib that does not excise the patient, the liver tumor patient is effectively implemented high-strength focusing ultrasonic therapy and become possibility as sensitizer.
Description of drawings
Fig. 1 is the sketch map that ultrasonic activation photosensitizer generation phonochemical reaction generates active oxygen:
Fig. 2 is the applicating flow chart of the photosensitizer of embodiment 1 as the high intensity focused ultrasound sensitizer
Fig. 3 is the applicating flow chart of the photosensitizer of embodiment 2 as the high intensity focused ultrasound sensitizer
The specific embodiment
Below be non-limiting examples of the present invention:
Embodiment 1: the high intensity focused ultrasound enhancement effect of observing photosensitizer on the cultured cell in vitro: cultivate target cell: select breast cancer cell, be incubated in 37 ℃ of incubators that contain 5% carbon dioxide, saturation vapour with the RPMI1640 culture fluid routine that contains 10% calf serum; Then, the take the logarithm target cell (2 * 10 of trophophase
4) individual cell, adding photosensitizer such as hemoporphyrin hatched 12～16 hours in 37 ℃ of incubators that contain 5% carbon dioxide, saturation vapour, owing to there is part photosensitizer hemoporphyrin not engulfed by target cell, also be free in the culture fluid, so before ultrasonic irradiation, washing is removed hemoporphyrin remaining in the culture fluid for several times; Then, using ultrasound ripple irradiation target cell.Under the ultrasonic irradiation effect, photosensitizer hemoporphyrin generation phonochemical reaction generates reactive oxygen species (as shown in Figure 1).Strengthen the therapeutic effect of high intensity focused ultrasound.Experiment adopts mtt assay to observe the application dose that photosensitizer can significantly reduce high intensity focused ultrasound, improves the killing-efficiency of its pair cell.Show that photosensitizer has significant high intensity focused ultrasound effect of enhanced sensitivity.As shown in Figure 2.
In present embodiment 1, the photosensitizer of selecting is a kind of safety non-toxic, the selective fixed photosensitizer that is positioned at the proliferative tissue cell of energy, except hemoporphyrin, also it can be aluminum phthalocyanine, 5-amino-laevulic acid, hypocrellin derivant, single asparagine chlorin, De Kesafei quinoline lutecium, rose-red or hematoporphyrin monomethyl ether etc.
High intensity focused ultrasound is JC type high-intensity focus supersonic tumor therapy system (being produced by Haifu (HIFU) Technology Co. Ltd., Chongqing) in embodiment 1.JC type high-intensity focus supersonic tumor therapy system mainly is made up of five parts such as power-adjustable generator, B ultrasonic monitoring system, treatment probe, mechanical movement control system, therapeutic bed harmony coupling devices.
Embodiment 2: observe the high intensity focused ultrasound enhancement effect of photosensitizer at body: the photosensitizer hemoporphyrin is adopted in intravascular injection or the target tissue directly inject, when treating that its selectivity is distributed in target tissue, use the high intensity focused ultrasound effect and produce phonochemical reaction down, strengthen the therapeutic effect of high intensity focused ultrasound, reduce the generation of complication in the high-strength focusing ultrasonic therapy process.As shown in Figure 3:
Experimental rabbit is transplanted VX in embodiment 2
2The tumor model adopts intramuscular anesthesia, is fixed on the high-strength focusing ultrasonic therapy bed, { is produced by Haifu (HIFU) Technology Co. Ltd., Chongqing } with JC type high-intensity focus supersonic tumor therapy system experimental rabbit is carried out irradiation.JC type high-intensity focus supersonic tumor therapy system mainly is made up of five parts such as power-adjustable generator, B ultrasonic monitoring system, treatment probe, mechanical movement control system, therapeutic bed harmony coupling devices.
Experimental rabbit is transplanted VX
2Tumor model random packet is that blank group (giving normal saline), simple photosensitizer group (only give hemoporphyrin, do not carry out high intensity focused ultrasound irradiation), simple high intensity focused ultrasound irradiation group (only carry out high intensity focused ultrasound irradiation, do not give hemoporphyrin) and enhanced sensitivity group (give hemoporphyrin and carry out high intensity focused ultrasound irradiation).Adopt high intensity focused ultrasound to be with B ultrasonic prescan target tissue (to transplant VX at random
2Tumor), after the selected good aspect, along auricular vein input hemoporphyrin, row fixed point or linear fashion (line length 1cm, scanning, speed 3mm/s) are carried out the high intensity focused ultrasound damage to tumor tissue, record target area grey scale change, treatment time.
Dissected in 24 hours behind the irradiation and draw materials, measure the radial line (length and width, thick) in target tissue damage location coagulation necrosis district, with formula: long * 1/2 wide * 1/2, V=4/3 π * 1/2 is thick, calculates the size of coagulation necrosis.Calculate EEF (the available efficiency factor, energy efficiency factor) according to formula EEF=η Pt/V (J/mm3), and carry out comparing between A, B group and in the group.η represents the high-intensity focusing ultrasonic transducer focusing factor in the formula, and its reflection high-intensity focusing ultrasonic transducer is got η=0.7 to the ability that ultrasonic energy converges; P is a high intensity focused ultrasound source total acoustic power (W); T is treatment total time (s); V is lesion volume (mm3).After the photosensitizer effect was found in experiment, the efficiency factor of target tissue significantly descended; Illustrate that photosensitizer is the high intensity focused ultrasound sensitizer of function admirable.Measurement data is represented with meansigma methods ± SD, adopts SPSS 10.0 for windows statistical packages, the t check.The result is as shown in table 1 below, and wherein, in the following table, P has significant differences (annotate: P herein is an italic, is not power) on the statistics.
The comparison of the EEF of each group of table 1
| Group | EEF(J/mm 3) |
| Simple high intensity focused ultrasound | 332.8±120.2 |
| Hemoporphyrin adds the high strength focus supersonic | 13.6±10.1 * |
*Compare P＜0.01 in twos
Claims (14)
1. photosensitizer is as the application of high intensity focused ultrasound sensitizer.
2. photosensitizer according to claim 1 is as the application of high intensity focused ultrasound sensitizer, it is characterized in that allowing the photosensitizer selectivity very/neoplasm sex organization in retention, utilize the acoustic enviroment of its selectivity target area retention characteristic changing target tissue, increase the target area ultrasound energy deposition, reduce high-strength focusing ultrasonic therapy dosage, activate photosensitizer generation phonochemical reaction with high intensity focused ultrasound and produce active oxygen and the irreversible damage pathological tissues, strengthen optimum, the neoplasm treatment of diseases effect of high-strength focusing ultrasonic therapy by sonochemistry mechanism.
3. photosensitizer according to claim 2 is as the application of high intensity focused ultrasound sensitizer, it is characterized in that described photosensitizer as sensitizer be safety non-toxic can selectivity very/neoplasm sex organization in retention and can be produced the material that oxidation reaction generates active oxygen by light or sound activation, these photosensitizer can be hydrophilic, lipophile, amphipathic.
4, photosensitizer according to claim 3 is as the application of high intensity focused ultrasound sensitizer, but it is characterized in that described photosensitizer is the photosensitizer of intravenous injection, intra-arterial injection or local injection.
5, photosensitizer according to claim 3 is characterized in that being selected from porphyrin and derivant thereof as the photosensitizer of high-strength focusing ultrasonic therapy enhanced sensitivity as the application of high intensity focused ultrasound sensitizer, phthalocyanine and derivant thereof, chlorophyll and derivant thereof, endogenous photosensitizers 5-amino-laevulic acid, phycobniliprotein class photosensitizer, five nitrogen tooth derivatives class photosensitizer, the quinones photosensitizer, rose-red, fullerene, polyacetylene class photosensitizer, the thiophenes photosensitizer, Chinese herbal medicine class photosensitizer hypocrellin, psoralen class and curcumin, hypericin, pseudohypericin, emodin, riboflavin, a kind of and wantonly two kinds or multiple mixture in the aloe-emodin.
6, photosensitizer according to claim 5 is as the application of high intensity focused ultrasound sensitizer, the photoactive substance that it is characterized in that or multiple combine arbitrary with the high intensity focused ultrasound auxiliary agent of any one or more mixture in the described photosensitizer and form, should be included in simultaneously to add in this photosensitizer has the material of pathoklisis to form the targeting sensitizing agent to tumor tissues or lesions position.
7, photosensitizer according to claim 6 is as the application of high intensity focused ultrasound sensitizer, it is characterized in that the described continuous phase that the high intensity focused ultrasound auxiliary agent that forms sensitizing agent comprises that the discontinuous phase that is made of filmogen parcel core and aqueous medium constitute that combines with photosensitizer, wherein said discontinuous phase is evenly dispersed in the described continuous phase, and the particle diameter of described discontinuous phase is 5nm～15 μ m.
8, photosensitizer according to claim 7 is characterized in that as the application of high intensity focused ultrasound sensitizer the filmogen of described auxiliary agent has biocompatibility, and the material of described core adopts gas, liquid or nano grade biological compatibility solid.
9, photosensitizer according to claim 8 is as the application of high intensity focused ultrasound sensitizer, and the filmogen that it is characterized in that described auxiliary agent is one or more materials in lipid, protide and the saccharide.
10, photosensitizer according to claim 9 is as the application of high intensity focused ultrasound sensitizer; it is characterized in that described lipid is selected from the 3-sn-phosphatidylcholine, 1 in the phospholipid; 2-two palmityls-sn-glyceryl-3-phosphatidyl glycerol base-sodium salt, 1; 2-distearyl acyl group-sn-glyceryl-3-phosphatidylcholine, 1; 2-two palmityls-sn-glyceryl-3-phosphatidyl acid-sodium salt, 1, one or more in 2-two palmityls-sn-glyceryl-3-phosphatidylcholine, Phosphatidylserine or the hydrogenated phospholipid acyl serine.
11, photosensitizer according to claim 8 is characterized in that the gas that described core material adopts is selected from air, nitrogen, one or more in carbon dioxide, fluorine carbon appropriate hydrocarbon gas or the alkanes gas as the application of high intensity focused ultrasound sensitizer.
12, photosensitizer according to claim 8 is characterized in that as the application of high intensity focused ultrasound sensitizer the liquid that described core material adopts is selected from C
5-C
6Alkane, C
5-C
12In fluorine carbon hydrocarbon, satisfied fatty acid, unsaturated fatty acid or the iodized oil one or more.
13, according to of the application of the described photosensitizer of one of claim 1～12 as the high intensity focused ultrasound sensitizer, it is characterized in that it being before high-strength focusing ultrasonic therapy is carried out in patient's target area 0～168 hour, by in intravenous drip or the target tissue directly injection mode give the patient infusion photosensitizer.
14, photosensitizer according to claim 13 is as the application of high intensity focused ultrasound sensitizer, it is characterized in that utilizing photoactive substance as sensitizer combining ultrasonic ripple embolotherapy tumor, nevus flammeus, it is before ultrasonic irradiation is carried out in patient's target area 0～168 hour, by in intravenous drip or the target tissue directly mode such as injection give the patient infusion photosensitizer, described ultrasound wave is for focusing on treatment that maybe can not focus on or the ultrasound wave of diagnosing usefulness, and its energy can be a low-intensity or also high-intensity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115551 CN1958093A (en) | 2005-11-04 | 2005-11-04 | Application of photosensitizer for high temperature focused ultrasonic sensitization agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510115551 CN1958093A (en) | 2005-11-04 | 2005-11-04 | Application of photosensitizer for high temperature focused ultrasonic sensitization agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1958093A true CN1958093A (en) | 2007-05-09 |
Family
ID=38070044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510115551 Pending CN1958093A (en) | 2005-11-04 | 2005-11-04 | Application of photosensitizer for high temperature focused ultrasonic sensitization agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1958093A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102233159A (en) * | 2010-05-06 | 2011-11-09 | 高春平 | Focused ultrasonic noninvasive sound powered tumor therapy system |
| CN103641712A (en) * | 2013-12-09 | 2014-03-19 | 哈尔滨医科大学 | Hydroxyl acetylated curcumin and application thereof in preparation of ultrasonic sensitive agent for treating atherosclerosis |
| CN108084311A (en) * | 2017-12-28 | 2018-05-29 | 宁波俐辰新能源有限公司 | A kind of ecologic planting nuisanceless light transmission film and its manufacturing method |
| CN117919402A (en) * | 2023-12-19 | 2024-04-26 | 中国科学院宁波材料技术与工程研究所 | Sensitizer for high-strength focused ultrasound and preparation method and application thereof |
-
2005
- 2005-11-04 CN CN 200510115551 patent/CN1958093A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102233159A (en) * | 2010-05-06 | 2011-11-09 | 高春平 | Focused ultrasonic noninvasive sound powered tumor therapy system |
| CN103641712A (en) * | 2013-12-09 | 2014-03-19 | 哈尔滨医科大学 | Hydroxyl acetylated curcumin and application thereof in preparation of ultrasonic sensitive agent for treating atherosclerosis |
| CN108084311A (en) * | 2017-12-28 | 2018-05-29 | 宁波俐辰新能源有限公司 | A kind of ecologic planting nuisanceless light transmission film and its manufacturing method |
| CN117919402A (en) * | 2023-12-19 | 2024-04-26 | 中国科学院宁波材料技术与工程研究所 | Sensitizer for high-strength focused ultrasound and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| You et al. | ROS-generating TiO2 nanoparticles for non-invasive sonodynamic therapy of cancer | |
| Galanzha et al. | Photoacoustic flow cytometry | |
| US20090220423A1 (en) | Method of activating a photosensitizer | |
| CN101130082A (en) | Novel photosensitive agent with function of carrying oxygen | |
| Wen et al. | On-demand phototoxicity inhibition of sensitizers and H2S-triggered in-situ activation for precise therapy of colon cancer | |
| Yan et al. | HematoPorphyrin Monomethyl Ether polymer contrast agent for ultrasound/photoacoustic dual-modality imaging-guided synergistic high intensity focused ultrasound (HIFU) therapy | |
| Wang et al. | Photoacoustic-guided photothermal therapy by mapping of tumor microvasculature and nanoparticle | |
| Gutwein et al. | Fractionated photothermal antitumor therapy with multidye nanoparticles | |
| KR20140110757A (en) | Use of Photosensitizer In Preparation of Virus-Inactivating Medicaments For Treating Diseases | |
| Liu et al. | Effect of microbubble-enhanced ultrasound on prostate permeability: A potential therapeutic method for prostate disease | |
| CN111249461A (en) | Preparation and application of phycocyanin-chlorin e6 covalent nanoparticles | |
| Verma et al. | Recent advancement of indocyanine green based nanotheranostics for imaging and therapy of coronary atherosclerosis | |
| CN1958093A (en) | Application of photosensitizer for high temperature focused ultrasonic sensitization agent | |
| CN100574811C (en) | A kind of particulate auxiliary agent for high-intensity focused ultrasound therapy and its application | |
| Daneshvar et al. | Fractionated sonodynamic therapy using gold@ poly (ortho-aminophenol) nanoparticles and multistep low-intensity ultrasound irradiation to treat melanoma cancer: In vitro and in vivo studies | |
| CN1803196A (en) | Fluorocarbon emulsion auxiliary agent for high-intensity focused ultrasound therapy and application thereof | |
| WO2020019306A1 (en) | Optical fiber puncture needle tube and application thereof | |
| CN100427142C (en) | An auxiliary agent for high-intensity focused ultrasound therapy and its screening method | |
| CN109966513B (en) | Preparation method and application of a multifunctional microbubble integrating ultrasound/fluorescence dual-modality imaging and photodynamic therapy/chemotherapy | |
| CN114668841B (en) | Activatable nano photosensitizer and preparation method and application thereof | |
| Qin et al. | An oxygen-enriched photodynamic nanospray for postsurgical tumor regression | |
| CN1298400C (en) | Method and equipment for setting medical care device of ultrasound microbubble contrast media to form embolism in capillary vessel | |
| CN100574810C (en) | A kind of plasmid auxiliary agent for high-intensity focused ultrasound therapy and its application | |
| Wang et al. | Combination of high-intensity focused ultrasound with nanoscale ultrasound contrast agent in treatment of rabbit breast VX2 tumors: a pilot study | |
| RU2295365C1 (en) | Laser therapy method for treating benign prostate hyperplasia cases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20070509 |